|
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company’s drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a Phase III clinical trial program for the treatment of obesity. It has a pipeline of compounds that target G protein-coupled receptors (GPCRs), and includes compounds being evaluated independently and with its partners, including Merck & Co., Inc. (Merck) and Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil-Janssen). On January 9, 2008, the Company acquired from Siegfried Ltd certain drug product facility assets, including a licensed production facility, fixtures, equipment, other personal property and real estate assets in Zofingen, Switzerland.
|
|
Around The Net
You are reading news provided by a variety of web sources.
Drug Pipeline
| Drug Name | Type Of Drug | FDA Status | Drug Phase |
| Lorcaserin |
Weight Loss
| Pending Decision | Phase 3 |
Events
FDA Panel Review:
FDA panel review.
(relates to the drug Lorcaserin)
FDA Decision:
FDA decision date.
(relates to the drug Lorcaserin)
Add New Event
In order to write a comment you must first login.
Login or Register (for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login or Register (for free!)
Add Link
|
ARNA
$6.86
9/3/2010 4:00:00 PM
Sponsors
|